Navigation Links
Atrium Medical Receives FDA Approval for its Novel C-QUR Lite(TM) V-Patch and C-QUR Edge(TM) V-Patch
Date:5/8/2008

HUDSON, N.H., May 8 /PRNewswire/ -- Atrium Medical Corporation is pleased to announce it has obtained US FDA 510(K) approval for two new Omega 3 surgical mesh products; C-QUR Edge(TM) V-Patch and C-QUR Lite(TM) V-Patch.

These new products are indicated for use in the surgical repair and reinforcement of soft tissue, including hernia repair -- a common procedure performed more than 700,000 times in the US each year. This novel technology combines Atrium's ProLite Ultra(TM) polypropylene surgical mesh with a proprietary, pharmaceutical grade Omega 3 fatty acid bio-absorbable gel coating. Atrium's discovery of combining an inert thin wall polypropylene mesh with an Omega 3 biological coating in pre-clinical studies has demonstrated a minimization of tissue attachment as well as a significant reduction in both foreign body reaction and inflammation, resulting in a well healed, reinforced repair.

C-QUR Edge(TM) V-Patch and C-QUR Lite(TM) V-Patch are designed to simplify umbilical, epigastric, trocar-site, and other small abdominal wall hernia repairs. C-QUR Edge(TM) V-Patch offers long-term protection from visceral tissue attachment when placed intra-abdominally while the C-QUR Lite(TM) version offers superior handling and healing characteristics for a pre-peritoneal repair.

The use of Atrium's all natural Omega 3 bio-absorbable coating with its advanced lightweight surgical mesh provides today's clinicians with a broad spectrum of options for soft tissue repair. Atrium's C-QUR Edge(TM) V-Patch and C-QUR Lite(TM) V-Patch will be available in a variety of sizes mid-year 2008.

About Atrium

Atrium's vast expertise in medical device technologies for the treatment of cardiovascular disease, hernia and adhesion prevention has brought a number of breakthrough advances in several diversified healthcare markets including interventional cardiology and radiology, chest trauma care and thoracic drainage, vascular surgery, and soft tissue rep
'/>"/>

SOURCE Atrium Medical Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Atrium Innovations Announces Management Changes
2. Atrium Innovations to Hold 2007 Third Quarter Financial Results Conference Call and Webcast on November 8
3. Atrium Announces a Significant Increase in Revenues and Earnings for the Third Quarter of 2007
4. Atrium Innovations to Hold 2007 Fourth Quarter and Full-Year Financial Results Conference Call and Webcast on February 29
5. Atrium Innovations to Hold 2008 First Quarter Financial Results Conference Call and Webcast on May 6
6. Atrium shows a strong financial performance for its first quarter
7. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
8. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
9. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
10. Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
11. BioMS Medical announces its intention to renew a normal course issuer bid
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... Conn. , March 5, 2015  UBM ... , a leading online community to help ... of the newest information available regarding the use ... of kidney cancer. March is ... are very few effective adjuvant treatment options for ...
(Date:3/5/2015)... 2015  In response to the incorrect assertions by ... on February 12, 2015. Impeto Medical SAS ... health and their SUDOSCAN® devices have been proven to ... prefers to have the courts decide this dispute rather ... 40 articles written by Key Opinion Leaders, published by ...
(Date:3/5/2015)... March 05, 2015 The next implants ... received the CE mark (European) approval. The CE mark ... Trade Association (EFTA) and the European Union. Following the ... been granted to implants supplied by the Turkey-based company ... , Osimplant's Cervical Expandable Bladed HA PEEK Cage ...
(Date:3/4/2015)... PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI ) today ... , 3.75% Convertible Senior Notes due May 1, 2015 (May ... principal amount or approximately $5.72 per share, effective March 3, 2015. ... adjusted in connection with the regular quarterly dividend of $0.15 ... own shares of PDL on March 5, 2015, the record date. ...
Breaking Biology Technology:OncoTherapy Network Highlights Kidney Cancer Awareness Month 2OncoTherapy Network Highlights Kidney Cancer Awareness Month 3Impeto Medical Responds to Published Allegations by LD Technology LLC ("LD") 2Invibio’s PEEK-OPTIMA® HA Enhanced Gains Momentum: New Implant Receives European Approval 2Invibio’s PEEK-OPTIMA® HA Enhanced Gains Momentum: New Implant Receives European Approval 3PDL BioPharma Announces Conversion Rate Adjustment for Convertible Note 2
... First Clinical Milestone Validates Approach, SAN FRANCISCO, ... completion of its first clinical trial, a,proof-of-concept study ... sodium channel blocker. Rufinamide was discovered and,developed by ... Europe as a,drug to treat a form of ...
... January 22 Progentix,Orthobiology B.V. announced today the ... was led by BioGeneration Ventures., Progentix Orthobiology ... suite of osteoinductive material products for clinical application,in ... based on,surface structured ceramic biomaterial scaffolds that have ...
... year the NorTech Venture,Capital Advisory Task Force reported in ... need to generate and attract over $1.2 billion,in venture ... needs of companies,located in Northeast Ohio. According to the ... the Cleveland+ region, to be,released in print mid February, ...
Cached Biology Technology:Synosia Announces Encouraging Results of Proof-of-Concept Clinical Trial for Epilepsy Drug rufinamide as a Treatment for Mood Disorders 2Synosia Announces Encouraging Results of Proof-of-Concept Clinical Trial for Epilepsy Drug rufinamide as a Treatment for Mood Disorders 3Progentix Orthobiology B.V. Closes Series A Financing Round 2Cleveland+ Region Attracts $318 Million in New Venture Investment in 2007 2Cleveland+ Region Attracts $318 Million in New Venture Investment in 2007 3Cleveland+ Region Attracts $318 Million in New Venture Investment in 2007 4Cleveland+ Region Attracts $318 Million in New Venture Investment in 2007 5
(Date:2/5/2015)... TRIANGLE PARK, North Carolina , 5. ... sein 35. Jahr als spezialisiertes Logistikunternehmen und ... Position als einzige klinische Logistikfirma (Clinical Logistics ... Die Kernbotschaft der neuen Kampagne lautet ... und Lieferungen. Foto: http://photos.prnewswire.com/prnh/20150205/173753 ...
(Date:2/5/2015)... Calif. , Jan. 27, 2015 /PRNewswire/ ... provider of globally deployed, innovative test solutions ... announced the delivery of its TS-323 ... Space Systems Company (LMSSC). GENASYS is a ... demands of mission-critical applications that require performance ...
(Date:2/5/2015)...  It is gratifying to see that the Obama ... science as a means to better understand human biology, ... was honored to participate in today,s White House event ... Since the 1980s my teams have been ... sequenced genome of a free living organism, the first ...
Breaking Biology News(10 mins):Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4J. Craig Venter, Ph.D., Co-Founder and CEO, Human Longevity, Inc. (HLI) Participates in White House Precision Medicine Event 2
... Therapeutic hypothermia has been proven to reduce mortality and ... was rarely used in a sample of more than ... Hypothermia and Temperature Management, a peer-reviewed journal published by ... www.liebertpub.com/ther Therapeutic hyperthermia was used in ...
... The American Association of Anatomists, 2012 Basmajian Award will ... professor in the department of cell biology, neurobiology and ... ceremony will take place at the AAA Annual Meeting ... Marquis & Marina, San Diego, CA)., This award recognizes ...
... Life (EOL, www.eol.org ) continues to expand at a ... At the start of 2012, EOL provides data on nearly ... rich information about conservation issues from the International Union for ... and videos than ever before. In the four ...
Cached Biology News:Todd Hoagland honored by Anatomy Society for excellence in teaching, research & scholarship 2The Encyclopedia of Life expanding at a record pace 2
Mouse Wnt-11 Affinity Purified Polyclonal Ab...
...
[14C]Polyethylene glycol 4000, 9.25 MBq, 250 uCi. Aqueous solution containing 3% ethanol, sterilized. 370-740 MBq/g, 10-20 mCi/g.1.85 MBq/ml, 50 uCi/ml. Category: Radiochemicals &Radiation Safety, ...
Use the DUALmembrane kit 3 to carry out DUALmembrane interaction analysis and cDNA library screening to characterize interactions between integral membrane proteins and to identify novel interaction ...
Biology Products: